Shares of Bio-Techne Corporation (NASDAQ: TECH) surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.
For the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.
The strong performance was driven by robust demand across Bio-Techne's product portfolio, particularly in its core Protein Sciences segment. The company also cited favorable foreign exchange rates as a tailwind.
"Bio-Techne's first quarter results reflect the continued execution of our core strategic priorities," said CEO Chuck Kummeth. "We are well-positioned to capitalize on growing end-market opportunities and remain committed to delivering long-term sustainable growth."免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。